Our disease selection strategy is centered on preclinical and clinical insight of amino acid biology. We have established a high throughput platform to discover and rationally design potent amino acid signatures. In order to build a predictive amino acid physiology network, we use bioinformatics and systems biology.
Next, using preclinical pharmacology, we demonstrate proof of principal in disease models and characterize amino acid profiles and evaluate how amino acids impact each other. This approach enables us to transform the traditional drug discovery process by significantly accelerating the speed of candidate generation to clinical validation within months.